| Suspended | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma NCT06806228 | Petrov, Andrey | Phase 1 |
| Recruiting | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma NCT06934889 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue NCT05756985 | Baptist Health South Florida | — |
| Recruiting | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma NCT05864534 | Northwestern University | Phase 2 |
| Recruiting | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma NCT05698524 | University of Nebraska | Phase 1 |
| Active Not Recruiting | Natural Progesterone for the Treatment of Recurrent Glioblastoma NCT05091866 | Emory University | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and R NCT05095376 | NRG Oncology | Phase 3 |
| Recruiting | Study of Pembrolizumab and M032 (NSC 733972) NCT05084430 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Completed | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune NCT04817254 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma NCT04397679 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Active Not Recruiting | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Gliobl NCT04528680 | Northwestern University | Phase 1 / Phase 2 |
| Recruiting | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed NCT04555577 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usu NCT04396860 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Gl NCT04216329 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblasto NCT04091503 | Center Trials & Treatment Europe | Phase 1 |
| Withdrawn | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Re NCT03014804 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG NCT03973918 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Sunitinib in Sarcomas of the Central Nervous System NCT03641326 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patient NCT03746080 | Lawrence D Recht | Phase 2 |
| Completed | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated G NCT03452930 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma NCT03275558 | Center Trials & Treatment | Phase 1 |
| Terminated | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer NCT03107780 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Multi-site Validation and Application of a Consensus DSC-MRI Protocol NCT03401866 | St. Joseph's Hospital and Medical Center, Phoenix | N/A |
| Active Not Recruiting | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma NCT03197506 | Mayo Clinic | Phase 2 |
| Completed | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children NCT03043391 | Istari Oncology, Inc. | Phase 1 |
| Completed | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma NCT03137888 | Emory University | Phase 2 |
| Active Not Recruiting | DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma NCT03115333 | ECOG-ACRIN Cancer Research Group | N/A |
| Completed | Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed NCT03174197 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery NCT03020017 | Northwestern University | EARLY_Phase 1 |
| Terminated | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma NCT02743078 | RTOG Foundation, Inc. | Phase 2 |
| Terminated | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma NCT02664363 | Daniel Landi | Phase 1 |
| Completed | BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab NCT03020602 | Seema Nagpal | Phase 1 |
| Terminated | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotira NCT02942264 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma NCT02101905 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects NCT02798406 | DNAtrix, Inc. | Phase 2 |
| Completed | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16 NCT02658981 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma NCT02709226 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma NCT02661282 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) NCT01931098 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primar NCT02502708 | NewLink Genetics Corporation | Phase 1 |
| Completed | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme NCT02386826 | SCRI Development Innovations, LLC | Phase 1 |
| Active Not Recruiting | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma NCT02455557 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Gliobla NCT02311920 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Recept NCT02573324 | AbbVie | Phase 3 |
| Active Not Recruiting | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT02152982 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma NCT03843814 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Terminated | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma NCT02133183 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma NCT02168270 | University of Nebraska | Phase 1 |
| Completed | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors NCT02052648 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Active Not Recruiting | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme NCT01903330 | Epitopoietic Research Corporation | Phase 2 |
| Completed | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma NCT01957956 | Mayo Clinic | EARLY_Phase 1 |
| Completed | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas NCT01837862 | Julie Krystal | Phase 1 / Phase 2 |
| Completed | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gl NCT01922076 | National Cancer Institute (NCI) | Phase 1 |
| Completed | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors NCT01975116 | Pediatric Brain Tumor Consortium | Phase 1 |
| Terminated | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Mul NCT01814813 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) NCT01856933 | Heinrich Elinzano, MD | Phase 2 |
| Terminated | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors NCT01836549 | Pediatric Brain Tumor Consortium | Phase 2 |
| Completed | Bevacizumab Beyond Progression (BBP) NCT01740258 | Duke University | Phase 2 |
| Terminated | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas NCT01721577 | Rush University Medical Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma NCT01250470 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors NCT01609790 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII NCT01454596 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | BIBF 1120 for Recurrent High-Grade Gliomas NCT01380782 | Patrick Y. Wen, MD | Phase 2 |
| Completed | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Ponti NCT01514201 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma NCT01498328 | Celldex Therapeutics | Phase 2 |
| Completed | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma NCT01480479 | Celldex Therapeutics | Phase 3 |
| Terminated | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Gliob NCT01430351 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) NCT01186406 | Duke University | Phase 2 |
| Terminated | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma NCT01227434 | University of California, San Francisco | Phase 2 |
| Completed | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients NCT01189266 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | AMG 102 and Avastin for Recurrent Malignant Glioma NCT01113398 | Katy Peters | Phase 2 |
| Completed | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions NCT01082926 | City of Hope Medical Center | Phase 1 |
| Completed | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosa NCT01149850 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Radiosurgery Plus Bevacizumab in Glioblastoma NCT01086345 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma NCT01004874 | Duke University | Phase 2 |
| Unknown | Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma NCT01124539 | Arno Therapeutics | Phase 2 |
| Completed | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme NCT00979017 | Katy Peters | Phase 2 |
| Completed | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Fo NCT00995007 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Gli NCT00879437 | Baylor College of Medicine | Phase 2 |
| Completed | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Tre NCT00960492 | Exelixis | Phase 1 |
| Withdrawn | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma NCT00734864 | Annick Desjardins | Phase 1 |
| Completed | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Gliob NCT00884741 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Sorafenib in Newly Diagnosed High Grade Glioma NCT00884416 | University Hospital, Geneva | Phase 1 |
| Terminated | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients Wi NCT00669669 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma NCT01095094 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gli NCT00734526 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma NCT02599090 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma NCT00936052 | Neurological Surgery, P.C. | Phase 2 |
| Terminated | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) NCT00735436 | Duke University | Phase 2 |
| Completed | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas NCT00734682 | University of California, San Francisco | Phase 1 |
| Completed | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma NCT00611325 | Duke University | Phase 2 |
| Completed | Dose-Intense Temozolomide in Recurrent Glioblastoma NCT00657267 | Patrick Y. Wen, MD | Phase 2 |
| Completed | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan NCT00613028 | Duke University | Phase 2 |
| Completed | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors NCT00667394 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas NCT00613223 | Annick Desjardins | Phase 1 |
| Completed | Ph I Dasatinib + Erlotinib in Recurrent MG NCT00609999 | Duke University | Phase 1 |
| Completed | Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma NCT00613054 | Annick Desjardins | Phase 1 |
| Completed | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma NCT00525525 | University of California, San Francisco | Phase 2 |
| Completed | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas NCT00612339 | Duke University | Phase 2 |
| Completed | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan f NCT00597402 | Duke University | Phase 2 |
| Completed | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors NCT00441142 | Patrick Y. Wen, MD | Phase 1 / Phase 2 |
| Completed | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme NCT00672243 | Duke University | Phase 2 |
| Completed | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG NCT00612430 | Duke University | Phase 2 |
| Completed | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) NCT00671970 | Duke University | Phase 2 |
| Completed | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients NCT00402116 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Terminated | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma NCT00365222 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma NCT00615927 | Duke University | Phase 2 |
| Completed | PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas NCT00612651 | Duke University | Phase 1 |
| Completed | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme NCT00165477 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG NCT00613132 | Annick Desjardins | Phase 1 |
| Completed | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma NCT00354913 | Duke University | Phase 2 |
| Completed | GW572016 to Treat Recurrent Malignant Brain Tumors NCT00107003 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas NCT00100802 | Children's Oncology Group | Phase 2 |
| Completed | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM NCT00612989 | Duke University | Phase 1 |
| Completed | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Glio NCT00612638 | Duke University | Phase 1 |
| Unknown | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma NCT00114309 | TransMolecular | Phase 2 |
| Completed | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tu NCT00187486 | University of California, San Francisco | Phase 2 |
| Completed | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) NCT00087451 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas NCT00610571 | Katy Peters | Phase 1 |
| Terminated | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) NCT00035373 | National Cancer Institute (NCI) | — |
| Completed | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade NCT00031083 | Biogen | Phase 1 |